SCIENCE

Our Science      

A recent renaissance in chemoproteomic technologies has been largely limited to targeting cysteine amino acids. Hyku Biosciences can covalently target histidine, tyrosine, or lysine amino acid within disease-causing proteins with high specificity to pursue more druggable binding pockets than cysteine-targeting. Our innovative, integrated platform can be utilized to develop small molecule therapeutics against a wide array of drug targets representing many target classes, including challenging “undruggable” proteins.

Crystal structure of a clinically relevant protein reveals greater targeting opportunities with histidine-, lysine- and tyrosine-binding pockets than cysteine-binding pockets

We are expanding the boundaries of drug discovery

Precision covalent targeting of functionally important histidines (H), tyrosines (Y), and lysines (K) in disease-causing proteins to discover novel medicines and improve patient lives

The Hyku Platform

Khyvalent P l a t f o r m

  • Covalent Chemistry– Proprietary Library of > 6000 Covalent Pharmacophores

    • Bespoke collection of pharmacophores that are orally bioavailable and well-suited for development 

  • Chemoproteomics

    • State-of-the art laboratory expanding the boundaries of chemoproteomics

    • Industry-leading histidine, tyrosine and lysine proteome maps generated using Hyku’s proprietary library

    • Global and focused chemoproteomic screening enable identification of druggable proteins and covalent binding sites with unparalleled breadth and depth 

  • Chemical Biology

    • Live cell screening integrating context-based chemoproteomics, cell biology and pharmacology

  • Machine Learning and Computational Chemistry

    • Machine learning algorithms for mining chemoproteomic data to guide target selection and prioritization

    • Integrated computational chemistry for rational drug design and hit to lead optimization